Sign In
Last checked at 
1 Aug 2024 07:00
Haleon plc: 2024 Half Year Results
1 August 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its half year results for the year ended 31 December 2024 are available at: http://www.rns-pdf.londonstockexchange.com/rns/6703Y_1-2024-7-31.pdf
The half year results statement will also be available on the Haleon website www.haleon.com/investors, and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Dividend
Consistent with our previous guidance to grow the dividend at least in line with earnings, the Board has declared a H1 2024 interim dividend of 2.0 pence per ordinary share, up 11% on the interim dividend in 2023. This interim dividend is expected to be paid on 19 September 2024 to holders of ordinary shares and US American Depositary Shares ("ADS") on the register as of 16 August 2024 (the record date). The ex-dividend date is expected to be 15 August 2024 for ordinary shareholders and 16 August 2024 for holders of ADS. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme ("DRIP"), the election deadline for the DRIP is 30 August 2024.
As previously stated, subject to market conditions and Board approval, Haleon expects to grow its ordinary dividend at least in line with adjusted earnings.
Presentation for analysts and shareholders
A recorded results presentation by Brian McNamara, Chief Executive Officer, and Tobias Hestler, Chief Financial Officer, will be available shortly after 7:00am BST (8:00am CEST) on 1 August 2024 and can be accessed at www.haleon.com/investors. This will be followed by a Q&A session at 9:00am BST (10:00am CEST).
For analysts and shareholders wishing to ask questions, please use the dial-in details below which will have a Q&A facility:
UK: | +44 (0) 800 358 1035 |
US: | +1 855 979 6654 |
All other: | +44 (0) 203 936 2999 |
Passcode: | 646174 |
An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors.
This information contains regulated information as per 6.3.7R of the Disclosure and Transparency Rules of the Financial Conduct Authority.
Amanda Mellor
Company Secretary
Enquiries
Investors | Media
| ||
Sonya Ghobrial | +44 7392 784784 | Zoë Bird | +44 7736 746167 |
Rakesh Patel | +44 7552 484646 | Gemma Thomas | +44 7985 175048 |
Emma White | +44 7823 523562 | ||
Email: investor-relations@haleon.com |
Email: corporate.media@haleon.com | ||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
Follow the stocks
